Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store. Reported by BioSpace on 2026-07-30.
Biogen
Biogen is a leading global biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. Its portfolio includes medicines for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, and rare diseases, with a growing late-stage neurology pipeline and recent expansion into rare diseases through the Reata Pharmaceuticals acquisition.
Company Info
Sector:Biotechnology / Neuroscience
Headquarters:Cambridge, Massachusetts, USA
Founded:1978
Website:www.biogen.com/
Upcoming Milestones & Key Dates
Q2 2026
Earnings
Q1 2026 Earnings — Reata integration and Leqembi commercial update
2026
Conference
Pipeline updates at R&D Day, including next-gen antisense programs
Clinical Development Pipeline
Leqembi (lecanemab)
Target: Anti-amyloid beta protofibril antibody (with Eisai)Skyclarys (omaveloxolone)
Target: Nrf2 activator (mitochondrial function)BIIB080
Target: Tau-targeting antisense oligonucleotide (ASO)Recent News
Biogen beats quarterly estimates as newer drugs drive growth
Biogen reported quarterly revenue and earnings above analyst estimates, driven by growth from newer products including Leqembi, Skyclarys, and Zurzuvae.
Leqembi records best quarter since launch as Biogen raises underlying guidance
Biogen's Leqembi recorded its best quarterly sales since launch as the Alzheimer's antibody continued to ramp, prompting the company to raise its underlying revenue guidance for the year.
Leqembi records best quarter since launch as Biogen raises underlying guidance
Leqembi records best quarter since launch as Biogen raises underlying guidance. Reported by Endpoints News on 2026-07-29.
AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug
New mid-stage data from Biogen's Ionis-partnered therapy diranersen validates the tau hypothesis in Alzheimer's disease.
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer's drugs
Biogen's tau-targeting Alzheimer's data shows promise but raises questions about dose response.
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Biogen defends anti-tau drug after stock slide
Biogen defends anti-tau drug after stock slide
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug, includes gallery
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug, includes gallery
Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi
Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi
Biogen targets immunology growth with $1 billion RayThera deal
Biogen targets immunology growth with $1 billion RayThera deal. (Reuters Biopharma.)
Leadership Team
Careers & Job Openings